全球过渡时期老龄化相关性黄斑部病变市场：各地区分析与预测（2025-2035）

过渡时期老龄化黄斑部病变是一种进行性视网膜疾病，常见于 50 岁或以上的人群，被认为是视力障碍的主要原因之一，尤其是对老年人而言。

过渡时期老龄化黄斑部病变盛行率的上升和全球人口老化是该市场的主要成长要素。除年龄外，遗传因素、吸烟和长时间暴露于紫外线也被认为是增加患病风险的因素。随着老年人口的持续增长，对有效治疗方法和诊断工具的需求预计将进一步增加，市场规模有望扩大。

老龄化黄斑部病变市场的一个关键发展是抗VEGF疗法的应用日益广泛。这些治疗方法已被证明在减缓湿性老龄化性黄斑部病变进展方面非常有效，其在过渡时期老龄化黄斑部病变的潜在应用也正在研究中。未来，预计抗VEGF疗法将被用作预防疾病发展至重症阶段的手段。细胞疗法、基因疗法以及其他创新候选疗法的出现也促进了市场的扩张。

除了药物治疗外，光同调断层扫瞄(OCT) 和眼底萤光(FAF) 等先进影像技术的使用，正在彻底改变过渡时期AMD 的诊断和后续观察。这些技术能够详细观察视网膜层级构造，从而能够在视力丧失进展之前及早发现疾病征兆。此外，人工智慧 (AI) 融入 OCT 和 FAF 影像分析，提高了诊断准确性，使其能够更有效地预测病情进展并制定个人化治疗方案。

此外，为解决过渡时期老龄化黄斑部病变所致的功能障碍，对视觉復健服务的需求日益增长。这些服务致力于最大限度地提高剩余视力并改善生活质量，这是推动市场成长的因素之一。随着研发的进步，过渡时期老龄化黄斑部病变市场未来有望实现更有针对性的治疗方法和更先进的诊断工具的实用化，从而推动市场持续扩张。

本报告调查了全球过渡时期老龄化黄斑部病变市场，并总结了主要趋势、影响市场的因素分析、法律制度、临床试验趋势、市场规模趋势和预测、各个细分市场、地区/主要国家的详细分析、竞争格局和主要企业的概况。

目录

执行摘要

第一章全球过渡时期老龄化黄斑部病变市场：产业展望

• 市场趋势
• 法律规范
• 过渡时期老龄化黄斑部病变的流行病学
• 临床试验分析
• 市场动态
  • 影响分析
  • 市场驱动因素
  • 市场挑战
  • 市场机会

第二章 全球过渡时期老龄化黄斑部病变市场（按地区）

• 北美洲
• 欧洲
• 亚太地区
  • 主要发现
  • 市场动态
  • 市场规模及预测

3. 全球过渡时期老龄化黄斑部病变市场：竞争格局与公司概况

• 主要发展和策略
  • M&A
  • 协同努力
  • 业务扩展和资金筹措
  • 产品发布和核准
  • 其他活动
• 公司简介
  • Novartis AG
  • Allegro Ophthalmics, LLC.
  • Apellis Pharmaceuticals

第四章调查方法

Global Intermediate Age-Related Macular Degeneration Market, Analysis and Forecast: 2025-2035

Intermediate age-related macular degeneration is a progressive retinal condition that typically affects individuals aged 50 and older. It is a major cause of vision impairment, particularly in the aging population. The growing prevalence of intermediate age-related macular degeneration, coupled with an aging global population, is a key driver of the market. In addition to aging, risk factors such as genetics, smoking, and prolonged exposure to sunlight contribute to the disease's increasing incidence. As the population continues to age, the demand for effective treatments and diagnostic tools for intermediate age-related macular degeneration is expected to grow, driving market expansion.

A critical development in the age-related macular degeneration market is the increasing use of anti-VEGF (vascular endothelial growth factor) therapies. These treatments have shown significant efficacy in slowing the progression of wet age-related macular degeneration, and while their use in intermediate age-related macular degeneration is still under investigation, they are expected to play a role in preventing the advancement to more severe stages. The growing availability of novel therapies, including cell and gene therapies and other innovative drug candidates, is also contributing to the market's expansion.

In addition to pharmacological treatments, the use of advanced imaging technologies such as optical coherence tomography (OCT) and fundus autofluorescence (FAF) is revolutionizing the diagnosis and monitoring of intermediate age-related macular degeneration. These imaging tools allow for a detailed examination of the retinal layers, enabling early detection of disease progression before significant vision loss occurs. The integration of artificial intelligence (AI) in the analysis of OCT and FAF images further enhances diagnostic precision, offering clinicians tools to predict disease progression and tailor treatment plans more effectively.

Moreover, the demand for vision rehabilitation services is rising as a means to help patients cope with the functional limitations imposed by intermediate age-related macular degeneration. These therapies, which focus on maximizing remaining vision and improving quality of life, are contributing to the market's growth. As research advances, the future of the intermediate age-related macular degeneration market holds promise for more targeted therapies and improved diagnostic tools, driving overall market expansion.

Despite the positive growth trajectory, several challenges continue to impact the global intermediate age-related macular degeneration market. One of the primary challenges is the high cost of advanced treatments, particularly anti-VEGF (vascular endothelial growth factor) injections, represents a significant financial challenge for both patients and healthcare systems. Anti-VEGF therapies are used to treat a variety of retinal diseases, such as age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. These treatments aim to inhibit the growth of abnormal blood vessels in the retina, which can lead to vision loss if left untreated.

Moreover, the side effects of current therapies may pose a major barrier to market growth, one of the most common risks associated with anti-VEGF injections is eye infections, such as endophthalmitis. This condition, although rare, can lead to severe complications, including vision loss. The risk of infection is especially concerning since the injections involve introducing medication directly into the eye, making it an invasive procedure.

As the global intermediate age-related macular degeneration market continues to grow, key trends such as advancements in early diagnostic technologies, the development of novel therapeutic approaches, and the increasing use of personalized treatments are expected to drive market expansion. The rising aging population and the growing awareness of the condition's impact on vision health are contributing to the higher demand for effective age-related macular degeneration treatments. Innovations in drug delivery systems, such as sustained-release intravitreal implants, and the increasing adoption of minimally invasive therapies are expected to enhance treatment outcomes and patient satisfaction. Additionally, research into genetic and environmental factors is paving the way for more tailored therapeutic options.

In conclusion, the global intermediate age-related macular degeneration market is set for robust growth, fueled by technological innovations in diagnostics and treatment, a rising aging demographic, and a growing focus on improving vision health. As healthcare providers and researchers continue to develop more effective and personalized therapies, there will be substantial opportunities for both new and established market players to address the unmet needs of age-related macular degeneration patients, ultimately improving patient outcomes and quality of life.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Intermediate Age-Related Macular Degeneration Market: Industry Outlook

• 1.1 Introduction
• 1.2 Market Trends
• 1.3 Regulatory Framework
• 1.4 Epidemiology of Intermediate Age-Related Macular Degeneration
• 1.5 Clinical Trial Analysis
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Challenges
  • 1.6.4 Market Opportunities

2. Global Intermediate Age-Related Macular Degeneration Market, by Region, $Million, 2023-2035

• 2.1 North America
  • 2.1.1 Key Findings
  • 2.1.2 Market Dynamics
  • 2.1.3 Market Sizing and Forecast
    • 2.1.3.1 North America Intermediate Age-Related Macular Degeneration Market, by Country
      • 2.1.3.1.1 U.S.
• 2.2 Europe
  • 2.2.1 Key Findings
  • 2.2.2 Market Dynamics
  • 2.2.3 Market Sizing and Forecast
    • 2.2.3.1 Europe Intermediate Age-Related Macular Degeneration Market, by Country
      • 2.2.3.1.1 Germany
      • 2.2.3.1.2 U.K.
      • 2.2.3.1.3 France
      • 2.2.3.1.4 Italy
      • 2.2.3.1.5 Spain
• 2.3 Asia Pacific
  • 2.3.1 Key Findings
  • 2.3.2 Market Dynamics
  • 2.3.3 Market Sizing and Forecast
    • 2.3.3.1 Asia Pacific Intermediate Age-Related Macular Degeneration Market, by Country
      • 2.3.3.1.1 Japan

3. Global Intermediate Age-Related Macular Degeneration Market: Competitive Landscape and Company Profiles

• 3.1 Key Developments and Strategies
  • 3.1.1 Mergers and Acquisitions
  • 3.1.2 Synergistic Activities
  • 3.1.3 Business Expansions and Funding
  • 3.1.4 Product Launches and Approvals
  • 3.1.5 Other Activities
• 3.2 Company Profiles
  • 3.2.1 Novartis AG
    • 3.2.1.1 Overview
    • 3.2.1.2 Top Products / Product Portfolio
    • 3.2.1.3 Target Customers/End-Users
    • 3.2.1.4 Key Personnel
    • 3.2.1.5 Analyst View
  • 3.2.2 Allegro Ophthalmics, LLC.
    • 3.2.2.1 Overview
    • 3.2.2.2 Top Products / Product Portfolio
    • 3.2.2.3 Target Customers/End-Users
    • 3.2.2.4 Key Personnel
    • 3.2.2.5 Analyst View
  • 3.2.3 Apellis Pharmaceuticals
    • 3.2.3.1 Overview
    • 3.2.3.2 Top Products / Product Portfolio
    • 3.2.3.3 Target Customers/End-Users
    • 3.2.3.4 Key Personnel
    • 3.2.3.5 Analyst View

4. Research Methodology

List of Figures

• Figure: Global Intermediate Age-Related Macular Degeneration Market (by Region), $Million, 2024 and 2035
• Figure: Epidemiology of Intermediate Age-Related Macular Degeneration
• Figure: Global Intermediate Age-Related Macular Degeneration Market Coverage
• Figure: Global Intermediate Age-Related Macular Degeneration Market Key Trends, Impact Analysis, 2023-2035
• Figure: Global Intermediate Age-Related Macular Degeneration Market, Competitive Landscape, January 2022-April 2025

List of Tables

• Table: Global Intermediate Age-Related Macular Degeneration Market, Clinical Trial Analysis
• Table: Global Intermediate Age-Related Macular Degeneration Market Dynamics, Impact Analysis
• Table: Global Intermediate Age-Related Macular Degeneration Market (by Region), $Million, 2023-2035